Kathleen Liu is Professor of Medicine and Anesthesia in the Divisions of Nephrology and Critical Care Medicine at the University of California, San Francisco. Dr. Liu has been an active member of numerous protocol development committees for the NHLBI ARDS Network and PETAL Network. She has co-led Phase 1 and 2 trials of mesenchymal stromal cell therapy for ARDS. During the COVID-19 pandemic, she was a Co-Principal investigator for the I-SPY COVID-19 trial, an open-label, phase 2 platform multicenter trial focused on novel therapies in patients with severe COVID-19.

Dr. Liu was a Steering Committee Member for the NIDDK funded Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study focused on long term outcomes of AKI. She is the current external steering committee chair for the NIDDK-funded Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) study. Dr. Liu is the co-principal investigator for LIBERATE-D, a trial focused on strategies to wean dialysis after dialysis-requiring AKI.